

1P-637-T100

Monoclonal Antibody to CD180 Phycoerythrin (PE) conjugated (100 tests)

Clone: G28-8

Isotype: Mouse IgG1

Specificity: The mouse monoclonal antibody G28-8 recognizes CD180, a 95-105 kDa TLR-like

glycoprotein expressed on peripheral blood monocytes and dendritic cells, mantle zone B cells and marginal zone B cells, but very weakly on germinal center B cells.

Regulatory Status: RUO

Immunogen: Human tonsillar B cells

Species Reactivity: Human

Preparation: The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum

conditions. The conjugate is purified by size-exclusion chromatography and

adjusted for direct use. No reconstitution is necessary.

Storage Buffer: The reagent is provided in stabilizing phosphate buffered saline (PBS) solution

containing 15mM sodium azide.

Storage / Stability: Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not

use after expiration date stamped on vial label.

Usage: The reagent is designed for Flow Cytometry analysis of human blood cells using

20 μl reagent / 100 μl of whole blood or 10° cells in a suspension.

The content of a vial (2 ml) is sufficient for 100 tests.

Expiration: See vial label

Lot Number: See vial label

Background: CD180, also known as RP105 (or Bgp95, LY64) is a type I membrane glycoprotein

of Toll-like receptor (TLR) family. Its cytoplasmic tail is short and unlike the TLRs, it lacks the TIR domain. CD180 expression is dependent on the coexpression of its helper molecule, MD-1, and mirrors that of TLR4 on antigen-presenting cells. CD180 regulates recognition of LPS and signaling in B cells, via interacting directly with the TLR4 signaling complex, inhibiting its ability to bind microbial ligands. Ligation of CD180 by monoclonal antibodies leads to B cell activation, upregulation

of CD80/CD86, and increase in cell size.



PRODUCT DATA SHEET

References:

*Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL: Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun;6(6):571-8.

*Yazawa N, Fujimoto M, Sato S, Miyake K, Asano N, Nagai Y, Takeuchi O, Takeda K, Okochi H, Akira S, Tedder TF, Tamaki K: CD19 regulates innate immunity by the toll-like receptor RP105 signaling in B lymphocytes. Blood. 2003 Aug 15;102(4):1374-80.

*Divanovic S, Trompette A, Petiniot LK, Allen JL, Flick LM, Belkaid Y, Madan R, Haky JJ, Karp CL: Regulation of TLR4 signaling and the host interface with pathogens and danger: the role of RP105. J Leukoc Biol. 2007 Aug;82(2):265-71.

*Kikuchi Y, Koarada S, Tada Y, Ushiyama O, Morito F, Suzuki N, Ohta A, Horiuchi T, Miyake K, Nagasawa K: Difference in B cell activation between dermatomyositis and polymyositis: analysis of the expression of RP105 on peripheral blood B cells. Ann Rheum Dis. 2001 Dec;60(12):1137-40.

*Valentine MA, Clark EA, Shu GL, Norris NA, Ledbetter JA: Antibody to a novel 95-kDa surface glycoprotein on human B cells induces calcium mobilization and B cell activation. J Immunol. 1988 Jun 15;140(12):4071-8.

*Clark EA, Shu GL, Lüscher B, Draves KE, Banchereau J, Ledbetter JA, Valentine MA: Activation of human B cells. Comparison of the signal transduced by IL-4 to four different competence signals. J Immunol. 1989 Dec 15;143(12):3873-80.

*Olson NE, Graves JD, Shu GL, Ryan EJ, Clark EA: Caspase activity is required for stimulated B lymphocytes to enter the cell cycle. J Immunol. 2003 Jun 15;170(12):6065-72.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.